FOLH1 and posterior cortical atrophy: PSMA-targeted radionuclide theranostics have been intensely studied over the last several years, resulting in the FDA approval of [68Ga]PSMA-11 and [18F]DCFPyL for PET imaging, and [177Lu]PSMA-617 for radiopharmaceutical therapy of PCa [8,24,25,26,27].